Q. Anti SCL 70 antibody is most strongly associated with

Explanation

## Correct Answer: B. Interstitial lung disease Anti-SCL-70 (anti-topoisomerase I) antibody is the most specific autoantibody in systemic sclerosis (scleroderma), present in 20–40% of SSc patients, particularly those with diffuse cutaneous disease. The critical association is with **interstitial lung disease (ILD)**, which occurs in 70–80% of anti-SCL-70 positive patients and is the leading cause of morbidity and mortality in this subset. The antibody targets topoisomerase I, an enzyme essential for DNA unwinding and repair; its presence correlates with pulmonary fibrosis severity and progressive decline in forced vital capacity (FVC). In Indian SSc cohorts, anti-SCL-70 positivity predicts early-onset ILD and worse pulmonary prognosis. The pathophysiology involves T-cell and B-cell autoimmunity against lung fibroblasts, driving myofibroblast differentiation and excessive collagen deposition in the interstitium. Anti-SCL-70 is therefore used as a prognostic marker to identify patients requiring aggressive pulmonary screening (HRCT, PFTs) and early immunosuppressive therapy. This antibody is NOT associated with myositis, calcinosis, or GAVE; these are linked to other SSc-specific antibodies (anti-PM-Scl, anti-centromere, anti-RNA polymerase III). ## Why the other options are wrong **A. Myositis** — Anti-SCL-70 does not cause myositis; myositis in connective tissue disease is associated with anti-Jo-1 (histidyl-tRNA synthetase) and other aminoacyl-tRNA synthetase antibodies, which define the antisynthetase syndrome. SSc-associated myositis is rare and linked to anti-PM-Scl antibodies, not anti-SCL-70. This is an NBE trap pairing autoimmune disease with a wrong antibody. **C. Calcinosis cutis** — Calcinosis cutis in SSc is most strongly associated with **anti-centromere antibody (ACA)** and limited cutaneous disease (lcSSc), not anti-SCL-70. Anti-SCL-70 is associated with diffuse cutaneous SSc, which has minimal calcinosis. The trap exploits confusion between SSc-specific antibodies and their distinct clinical phenotypes. **D. GAVE** — Gastric antral vascular ectasia (GAVE) is a vascular complication of SSc but is NOT specifically associated with anti-SCL-70. GAVE occurs in both anti-centromere and anti-SCL-70 positive patients, and is more a feature of SSc-related GI involvement than a marker-specific complication. This option distracts by listing a real SSc manifestation without the correct antibody link. ## High-Yield Facts - **Anti-SCL-70 (anti-topoisomerase I)** is present in 20–40% of SSc patients and is the most specific antibody for diffuse cutaneous SSc (dcSSc) - Anti-SCL-70 positivity predicts **early-onset and progressive interstitial lung disease (ILD)** in 70–80% of carriers, making it the strongest prognostic marker for pulmonary fibrosis - **Anti-centromere antibody (ACA)** is associated with limited cutaneous SSc, calcinosis cutis, and pulmonary hypertension—NOT anti-SCL-70 - Anti-SCL-70 targets **topoisomerase I**, an enzyme critical for DNA repair; antibody-mediated dysfunction drives fibroblast activation and lung collagen deposition - In Indian SSc cohorts, anti-SCL-70 positive patients require **baseline HRCT and PFTs** for early ILD detection and immunosuppressive therapy initiation (mycophenolate, cyclophosphamide) ## Mnemonics **SSc Antibody–Phenotype Link** **SCL-70 = Diffuse + Lung; ACA = Limited + Calcinosis**. Anti-SCL-70 → diffuse skin disease + ILD (pulmonary fibrosis). Anti-centromere → limited skin + calcinosis + PH. Use this to instantly match antibody to clinical picture. ## NBE Trap NBE pairs anti-SCL-70 with myositis (option A) to exploit confusion between SSc-specific antibodies and antisynthetase syndrome, which truly causes myositis. The trap also lists calcinosis (option C), a real SSc feature but linked to anti-centromere, not anti-SCL-70. ## Clinical Pearl In Indian rheumatology practice, anti-SCL-70 seropositivity in a patient with early SSc is a red flag for aggressive pulmonary screening and early cyclophosphamide or mycophenolate initiation to slow ILD progression—delaying treatment in this subset significantly worsens long-term FVC decline and survival. _Reference: Robbins & Cotran Pathologic Basis of Disease, Ch. 5 (Immunopathology); Harrison's Principles of Internal Medicine, Ch. 279 (Systemic Sclerosis)_